Pfizer’s $PFE Demand Zone — Ready to Explode?Hey traders, it’s Alfonso Moreno from Set and Forget! Today, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to
Key facts today
Pfizer's Q3 revenue was $16.65 billion, down 5.9% year-on-year. Adjusted EPS was $0.87, exceeding estimates. Full-year revenue outlook is $61-$64 billion, with EPS forecast of $3-$3.15.
Pfizer raised its Metsera bid to $8.1 billion amid competition from Novo Nordisk's $10 billion offer. Pfizer is pursuing legal action to uphold their merger agreement.
Pfizer's earnings reports are currently under scrutiny by investors, reflecting ongoing interest in the company's financial performance amid recent market activity.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.60 EUR
7.75 B EUR
61.46 B EUR
5.68 B
About Pfizer, Inc.
Sector
Industry
CEO
Albert Bourla
Website
Headquarters
New York
Founded
1849
ISIN
CA7170651060
FIGI
BBG015CD5H66
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Related stocks
PFE QuantSignals V3 Earnings 2025-11-03PFE QuantSignals V3 Earnings 2025-11-03
PFE Earnings Signal | 2025-11-03
• Direction: BUY CALLS | Confidence: 72%
• Entry Plan: Open | Expiry 2025-11-07
• Strike Focus: $24.50
• Entry Range: $0.47
• Target 1: $0.94
• Stop Loss: $0.28
• Implied Move: $1.12 (4.6%)
• 24h Move: +0.06%
• Flow Intel: Bull
Pfizer “shows its claws”: between litigation&boost searchPfizer “shows its claws”: between litigation and the search for a new boost
By Ion Jauregui – Analyst at ActivTrades
Pfizer (NYSE: PFE) is back in Wall Street’s spotlight after filing a lawsuit against Metsera (NASDAQ: MTSR) and Novo Nordisk (CPH: NOVOb), accusing them of breaching a merger agr
Back test before continuationNYSE:PFE after breaking out on trump deal and now working with him to sell their products through TrumpRx launching next year. They are also exempt from tariffs for 3 years and plan to invest 60B in the US. good support/resistance flip could take place here would like to hold 25 but 24 is possible.
Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience?Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience? $28.90 in Sight? 📈
At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boo
Pfizer and Pharma Stocks Rise After Trump DecisionPfizer Inc. (PFE) and Other Pharmaceutical Stocks Rise Following Trump’s Decision
According to media reports, US President Donald Trump launched a website allowing Americans to purchase medicines directly. He announced that Pfizer would offer some of its drugs on this platform and introduce new me
Pfizer medium term outlook.This giant might not make you rich, but its in my opinion a safe bet for 2025>2026.
I have personally opened a long position due to my analysis.
Check my old bitcoin predictions from 4 years ago and you will see my eye is strong for longer term moves.
Make your own analysis and decision, this is
PFE: Bears Trapped at Multi-Year Lows - Spring Ready to Uncoil📍 **To see my confluences and/or linework:**
Step 1: Grab chart 📊
Step 2: Unhide Group 1 in object tree 🎯
Step 3: Hide and unhide specific confluences one by one ✨
Step 4: Double-click the screen to show RSI, MFI, CVD, and OBV indicators alongside divergence markings 📈
Title: 💊 PFE: Bears Trapp
Pfizer: Bearish Setup Points to Further Downside Risk Current Price: $23.76
Direction: SHORT
Targets:
- T1 = $22.50
- T2 = $21.50
Stop Levels:
- S1 = $24.50
- S2 = $25.30
**Wisdom of Professional Traders:**
This analysis synthesizes insights from thousands of professional traders and market experts who have been following Pfizer’s
Pfizer: Long-Term Downtrend Still in Effect?Pfizer has spent almost two years consolidating after a major slide. Now some traders may see the long-term downtrend reasserting itself.
The first pattern on today’s chart is the pair of highs in July and August just above $26, which could be viewed as a double-top reversal pattern.
Second, the d
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
P
PFE5588844
Pfizer Investment Enterprises Pte. Ltd. 5.34% 19-MAY-2063Yield to maturity
5.68%
Maturity date
May 19, 2063
P
PFE5588843
Pfizer Investment Enterprises Pte. Ltd. 5.3% 19-MAY-2053Yield to maturity
5.57%
Maturity date
May 19, 2053
P
PFE5588591
Pfizer Investment Enterprises Pte. Ltd. 5.11% 19-MAY-2043Yield to maturity
5.38%
Maturity date
May 19, 2043
See all PFEB bonds
Curated watchlists where PFEB is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S stocks are traded under the ticker PFEB.
PFEB reached its all-time high on Jan 15, 2009 with the price of 104.45 EUR, and its all-time low was 6.05 EUR and was reached on Apr 9, 2025. View more price dynamics on PFEB chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financials in yearly and quarterly reports right on TradingView.
Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S is going to release the next earnings report on Feb 3, 2026. Keep track of upcoming events with our Earnings Calendar.
PFEB earnings for the last quarter are 0.74 EUR per share, whereas the estimation was 0.54 EUR resulting in a 37.52% surprise. The estimated earnings for the next quarter are 0.58 EUR per share. See more details about Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S earnings.
Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S revenue for the last quarter amounts to 14.19 B EUR, despite the estimated figure of 14.06 B EUR. In the next quarter, revenue is expected to reach 15.41 B EUR.
PFEB net income for the last quarter is 2.45 B EUR, while the quarter before that showed 2.74 B EUR of net income which accounts for −10.70% change. Track more Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financial stats to get the full picture.
No, PFEB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2025, the company has 81 K employees. See our rating of the largest employees — is Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S EBITDA is 21.80 B EUR, and current EBITDA margin is 36.93%. See more stats in Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financial statements.
Like other stocks, PFEB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S stock right from TradingView charts — choose your broker and connect to your account.
















